Search Within

GME, Medicine

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (183)
  2. Journal Article (144)
  3. Research Letter (9)
  4. Review (3)
  5. Correspondence (1)
Groups
  1. Biostatistics Service (340)
  2. Epidemiology and Biostatistics (340)
  3. Graduate Medical Education (340)
  4. Department of Medicine (328)
  5. Hematologic Malignancies, Division of (224)
  6. Hematology-Oncology Fellows (214)

More Groups

People
  1. Gunjan Shah (93)
  2. Michael Scordo (93)
  3. Andriy Derkach (89)
  4. Sergio Giralt (84)
  5. Malin Hultcrantz (69)
  6. Kylee Maclachlan (67)

More People

Years
  1. 2025 (23)
  2. 2024 (85)
  3. 2023 (114)
  4. 2022 (72)
  5. 2021 (24)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (76)
  2. Blood (64)
  3. Clinical Lymphoma, Myeloma and Leukemia (24)
  4. Clinical Cancer Research (13)
  5. Annals of Oncology (12)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Clinical Oncology (83)
  2. American Society of Hematology (74)
  3. Elsevier Inc. (45)
  4. Nature Publishing Group (29)
  5. Oxford University Press (20)
  6. American Association for Cancer Research (17)

More Publishers

Results (340)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Research Letter

    Bewersdorf, J. P.; Stahl, M.; Taylor, J.; Mi, X.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Lu, S. X.; Bourcier, J.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer
    Journal Article

    Shen, S.; Chen, Y.; Carpio, A.; Chang, C.; Iyengar, N. M.
    Cancer (2023)

    Fulltext@MSK | Save
  • Exocrine pancreatic insufficiency induced by immune checkpoint inhibitors
    Journal Article

    Satish, D.; Lin, I. H.; Flory, J.; Gerdes, H.; Postow, M. A.; Faleck, D. M.
    The Oncologist (2023)

    Fulltext@MSK | Save
  • HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer
    Journal Article

    Shen, S.; Ma, W.; Brown, D.; Da Cruz Paula, A.; Zhou, Q.; Iaosonos, A.; Tessier-Cloutier, B.; Ross, D. S.; Troso-Sandoval, T.; Reis-Filho, J. S.; more...
    Modern Pathology (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save